share_log

金斯瑞生物科技：海外監管公告: 上市附屬公司傳奇生物科技股份有限公司截至二零二三年十二月三十一日止的年度報告

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

香港交易所 ·  Mar 19 19:36
Summary by Futu AI
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）於2024年3月19日宣布，其上市附屬公司傳奇生物科技股份有限公司（「傳奇生物」），已向美國證券交易委員會提交截至2023年12月31日的年度報告20-F表格。傳奇生物為金斯瑞生物科技的非全資附屬公司，其股份以美國存託股份形式在美國納斯達克全球精選市場上市。該年度報告的詳細內容已在美國證監會網站公開。金斯瑞生物科技提醒股東及潛在投資者注意投資風險，並應審慎買賣或擬買賣公司證券。公告中提及的執行董事包括章方良博士、孟建革先生、王燁女士及朱力博士，非執行董事為王魯泉博士、潘躍新先生及王佳芬女士，以及獨立非執行董事郭宏新先生、戴祖勉先生、潘九安先生及王學海博士。
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）於2024年3月19日宣布，其上市附屬公司傳奇生物科技股份有限公司（「傳奇生物」），已向美國證券交易委員會提交截至2023年12月31日的年度報告20-F表格。傳奇生物為金斯瑞生物科技的非全資附屬公司，其股份以美國存託股份形式在美國納斯達克全球精選市場上市。該年度報告的詳細內容已在美國證監會網站公開。金斯瑞生物科技提醒股東及潛在投資者注意投資風險，並應審慎買賣或擬買賣公司證券。公告中提及的執行董事包括章方良博士、孟建革先生、王燁女士及朱力博士，非執行董事為王魯泉博士、潘躍新先生及王佳芬女士，以及獨立非執行董事郭宏新先生、戴祖勉先生、潘九安先生及王學海博士。
Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”) announced on March 19, 2024 that its publicly traded subsidiary Legendary Biotechnology Co., Ltd. (“Legendary Biotech”) has filed Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. Legendary Bios is a non-wholly-owned subsidiary of Kingsley Biotechnology, whose shares are listed on the U.S. Nasdaq Global Select Market as U.S. Depository Shares. Details of the annual report are available on the website of the United States Securities and Exchange Commission. Kingsway Biotechnology reminds shareholders and potential investors to be aware of investment risks and to buy or intend to trade company securities with caution. The Executive Directors mentioned in the announcement are Dr. Zhang Fangliang, Mr. Meng Jiangjing, Ms. Wang Ye and Dr. Zhu Li. Non-Executive Directors are Dr. Wang Luquan, Mr. Pan Yuxin and Ms. Wang Jiafen, as well as Independent Non-Executive Directors Mr. Kwok Hongxin, Mr. Dai Zu-ming, Mr. Pan Jiuan and Dr. Wang Xuhai.
Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”) announced on March 19, 2024 that its publicly traded subsidiary Legendary Biotechnology Co., Ltd. (“Legendary Biotech”) has filed Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. Legendary Bios is a non-wholly-owned subsidiary of Kingsley Biotechnology, whose shares are listed on the U.S. Nasdaq Global Select Market as U.S. Depository Shares. Details of the annual report are available on the website of the United States Securities and Exchange Commission. Kingsway Biotechnology reminds shareholders and potential investors to be aware of investment risks and to buy or intend to trade company securities with caution. The Executive Directors mentioned in the announcement are Dr. Zhang Fangliang, Mr. Meng Jiangjing, Ms. Wang Ye and Dr. Zhu Li. Non-Executive Directors are Dr. Wang Luquan, Mr. Pan Yuxin and Ms. Wang Jiafen, as well as Independent Non-Executive Directors Mr. Kwok Hongxin, Mr. Dai Zu-ming, Mr. Pan Jiuan and Dr. Wang Xuhai.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.